The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Lineage Cell Therapeutics Inc shares valued at $8,850 were purchased by Howe Jill Ann on Nov 26 ’24. At $0.59 per share, Howe Jill Ann acquired 15,000 shares. The insider’s holdings grew to 25,500 shares worth approximately $14534.999999999998 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Samuel George A. III purchased 15,000 shares, netting a total of over 9,000 in proceeds. Following the buying of shares at $0.60 each, the insider now holds 22,184 shares.
Before that, Mulroy Michael H. had added 40,000 shares to its account. In a trade valued at $22,640, the Director bought Lineage Cell Therapeutics Inc shares for $0.57 each. Upon closing the transaction, the insider’s holdings increased to 40,000 shares, worth approximately $0.17 million.
As published in their initiating research note from Craig Hallum on August 20, 2024, Lineage Cell Therapeutics Inc [LCTX] has been a Buy and the price target has been revised to $4. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in early November. As of June 14, 2022, B. Riley Securities has initiated its “Buy” rating for LCTX. Earlier on August 19, 2021, Noble Capital Markets initiated its rating. Their recommendation was “an Outperform” for LCTX stock.
Analyzing LCTX Stock Performance
During the last five days, there has been a surge of approximately 0.42%. Over the course of the year, Lineage Cell Therapeutics Inc shares have dropped approximately -47.60%. Shares of the company reached a 52-week high of $1.6100 on 03/28/24 and a 52-week low of $0.5000 on 11/22/24. A 50-day SMA is recorded $0.8120, while a 200-day SMA reached $0.9895. Nevertheless, trading volume fell to 1.3 million shares from 6.73 million shares the previous day.
Support And Resistance Levels for Lineage Cell Therapeutics Inc (LCTX)
According to the 24-hour chart, there is a support level at 0.5301, which, if violated, would cause prices to drop to 0.4891. In the upper region, resistance lies at 0.6021. The next price resistance is at 0.6331. RSI (Relative Strength Index) is 36.68 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0919, which suggests the price will decrease in the coming days. Percent R is at 83.70%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
